We're scooping up shares of 2 stocks that fell victim to a September swoon

Jim Cramer's Charitable Trust bought 80 shares of Bank of New York at about $146.71 and 50 shares of Cardinal Health at about $223.58, lifting portfolio weights to roughly 2.1% and 2.7%, respectively. The purchases follow declines of more than 10% for BNY and about 10% for Cardinal Health since early September, with the trust viewing the market as oversold. Softer August PCE inflation and falling bond yields have reduced expectations for an October Fed rate increase, while Leerink reaffirmed Cardinal Health's growth prospects after meeting with management.

Analysis

The disclosed purchases are immaterial to fundamentals but can create a short-lived retail-following bid; do not confuse that flow with thesis validation. For BNY Mellon (BK; article labels it BNY), the relevant macro is not simply lower yields but the shape and volatility of the curve: a rapid front-end rally can pressure reinvestment yields and net interest revenue, while lower rate volatility and healthier capital markets improve custody, collateral-management and asset-servicing activity. BK's institutional client base makes retail cash-sorting a weak read-through, but persistent deposit repricing or weaker AUM-linked fee growth would still cap multiple expansion over the next 1-3 quarters.

CAH has a better company-specific pathway: specialty pharmacy, at-home care and services mix can compound earnings even if broad healthcare utilization moderates. The key second-order risk is that distributor earnings quality increasingly depends on higher-margin businesses that require investment and execution; any deceleration in specialty contribution, adverse drug-pricing policy, or working-capital build would expose a premium valuation versus peer McKesson (MCK). Analyst meeting commentary is not an independent catalyst; the next confirmatory event is guidance durability and cash conversion.

Contrarian view: an oversold-market bounce is a poor standalone reason to add either name. BK is more attractive only if the rate-cut narrative evolves into a soft landing rather than recession, whereas CAH can remain relatively defensive but is vulnerable if investors rotate from earnings durability into higher-beta healthcare. The preferable structure is selective relative value rather than an outright sector-beta trade.

Key Decisions for Investors

• Watch, rather than chase, BK on any Cramer-related strength; initiate a 1-3 month long only if it holds above the post-alert low and management maintains net interest revenue and fee-income guidance. Falsifier: a guidance cut tied to deposit costs, falling client balances, or materially weaker AUM/market activity.
• Prefer a 6-12 month long CAH / short MCK pair in equal dollar beta-adjusted sizing only if CAH's next results show specialty and at-home growth with stable operating cash conversion. Target relative upside is 8-12%; exit if CAH's segment margin or free-cash-flow conversion misses guidance while MCK maintains it.
• For a macro expression, avoid broad financials exposure through XLF: regional-bank and retail-deposit sensitivity can overwhelm BK's institutional franchise. If the curve steepens through a soft-landing repricing over the next 1-3 months, BK should outperform XLF; unwind the relative long if unemployment or credit-spread widening signals a recessionary steepener.
• Set an earnings alert for CAH: a reduction in capital-return capacity, an inventory/receivables-led cash-flow miss, or weaker specialty-services outlook would invalidate the quality-growth premise and warrants reducing exposure regardless of the headline share-price pullback.